Gaps in Care and Awareness of Fecal Microbiota Transplant for C. difficile

Gaps in Care and Awareness of Fecal Microbiota Transplant for C. difficile The Canadian Agency for Drugs and Technologies in Health (CADTH) launched a research project to determine how Canadian patients access fecal microbiota transplant (FMT). Currently, fecal transplant is [...]

2020-10-07T08:21:27-07:00August 7, 2020|

GI Society and CSIR Provide Input to PMPRB Consultations

GI Society and CSIR Provide Input to PMPRB Consultations On August 4, 2020, the Gastrointestinal Society and its partner charity, the Canadian Society of Intestinal Research, provided input on the Patented Medicine Prices Review Board (PMPRB) 2020 Draft Guidelines. These [...]

2020-10-07T07:43:24-07:00August 6, 2020|

Access to Innovative Medicines for Canadian Patients

Access to Innovative Medicines for Canadian Patients The Gastrointestinal Society continues to advocate for system-wide improvements in care and treatment for people with GI and liver diseases and disorders, ensuring that all patients have affordable and timely access to appropriate [...]

2020-06-10T10:27:06-07:00April 29, 2020|

Forced Switching Policies: Will Ontario be Next?

January 29, 2020 Gail Attara President & Chief Executive Officer, Gastrointestinal Society President, Canadian Society of Intestinal Research Forced Switching Policies: Will Ontario be Next? Government-led initiatives have never shown us so clearly how invasive their roles can become in [...]

2020-07-29T08:26:52-07:00January 29, 2020|

Short-sighted policies, clickbait savings, and long-term damage to IBD patients

Short-sighted policies, clickbait savings, and long-term damage to IBD patients December 18, 2019 Gail Attara President & Chief Executive Officer, Gastrointestinal Society President, Canadian Society of Intestinal Research   Alberta’s policy decision to switch the treatments of thousands of patients [...]

2020-04-01T15:43:22-07:00December 18, 2019|
Go to Top